Effects of low-level laser on the expression of interleukin-6, tumor necrosis factor‑α, osteoprotegerin, and receptor activator of nuclear factor-κB ligand in human periodontal ligament cells.
10.7518/hxkq.2023.2023133
- Author:
Meng TANG
1
;
Zhan-Qin CUI
1
;
Yangyang WANG
1
;
Zengguo CHEN
2
;
Wenjing LI
2
;
Cuiping ZHANG
3
Author Information
1. Dept. of Orthodontics, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
2. Dept. of Oral Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang 050000, China.
3. Dept. of Stomatology, Yongding District Hospital of Longyan City, Fujian Province, Longyan 364100, China.
- Publication Type:Journal Article
- Keywords:
high glucose environment;
human periodontal ligament cells;
interleukin-6;
low-level laser;
osteoprotegerin;
receptor activator of nuclear factor-κB ligand;
tumor necrosis factor-α
- MeSH:
Humans;
Osteoprotegerin;
Tumor Necrosis Factor-alpha/metabolism*;
Interleukin-6/pharmacology*;
RANK Ligand/pharmacology*;
Periodontal Ligament/metabolism*;
Lasers;
Glucose/pharmacology*
- From:
West China Journal of Stomatology
2023;41(5):521-532
- CountryChina
- Language:English
-
Abstract:
OBJECTIVES:This study aims to determine the effects of low-level laser (LLL) on the expression of interleukin-6 (IL-6), tumor necrosis factor (TNF)-α, osteoprotegerin (OPG), and receptor activator of nuclear factor-κB ligand (RANKL) in human periodontal ligament cells (HPDLCs) stimulated by high glucose; and identify the molecular mechanism of LLL therapy in the regulation of periodontal inflammation and bone remodeling during orthodontic treatment in diabetic patients.
METHODS:HPDLCs were cultured in vitro to simulate orthodontic after loading and irradiated with LLL therapy. The cultured cells were randomly divided into four groups: low glucose Dulbecco's modification of Eagle's medium (DMEM)+stress stimulation (group A), high glucose DMEM+stress stimulation (group B), hypoglycemic DMEM+LLL therapy+stress stimulation (group C), and hyperglycemic DMEM+LLL therapy+stress stimulation (group D). Groups C and D were further divided into C1 and D1 (energy density: 3.75 J/cm2) and C2 and D2 (energy density: 5.625 J/cm2). Cells in groups A, B, C, and D were irradiated by LLL before irradiation. At 0, 12, 24, 48, and 72 h, the supernatants of the cell cultures were extracted at regular intervals, and the protein expression levels of IL-6, TNF-α, OPG, and RANKL were detected by enzyme-linked immunosorbent assay.
RESULTS:1) The levels of IL-6 and TNF-α secreted by HPDLCs increased gradually with time under static pressure stimulation. After 12 h, the levels of IL-6 and TNF-α secreted by HPDLCs in group A were significantly higher than those in groups B, C1, and C2 (P<0.05), which in group B were significantly higher than those in groups D1, and D2 (P<0.01). 2) The OPG protein concentration showed an upward trend before 24 h and a downward trend thereafter. The RANKL protein concentration increased, whereas the OPG/RANKL ratio decreased with time. Significant differen-ces in OPG, RANKL, and OPG/RANKL ratio were found among group A and groups B, C1, C2 as well as group B and groups D1, D2 (P<0.05).
CONCLUSIONS:1) In the high glucose+stress stimulation environment, the concentrations of IL-6 and TNF-α secreted by HPDLCs increased with time, the expression of OPG decreased, the expression of RANKL increased, and the ratio of OPG/RANKL decreased. As such, high glucose environment can promote bone resorption. After LLL therapy, the levels of IL-6 and TNF-α decreased, indicating that LLL therapy could antagonize the increase in the levels of inflammatory factors induced by high glucose environment and upregulate the expression of OPG in human HPDLCs, downregulation of RANKL expression in HPDLCs resulted in the upregulation of the ratio of OPG/RANKL and reversed the imbalance of bone metabolism induced by high glucose levels. 2) The decrease in inflammatory factors and the regulation of bone metabolism in HPDLCs were enhanced with increasing laser energy density within 3.75-5.625 J/cm2. Hence, the ability of LLL therapy to modulate bone remodeling increases with increasing dose.
